New combo aims to wipe out breast cancer before surgery
NCT ID NCT06967103
First seen Jan 11, 2026 · Last updated May 23, 2026 · Updated 15 times
Summary
This study tests whether adding the drug QL1706 to standard chemotherapy can eliminate more cancer before surgery in people with early HR+/HER2- breast cancer. About 238 participants will receive either the combination or chemo alone for 6 cycles, then have surgery. After surgery, those who got QL1706 may continue it for up to 6 months. The main goal is to see if the cancer is completely gone at the time of surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan cancer hospital
RECRUITINGZhengzhou, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.